The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2019

Filed:

Sep. 02, 2014
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Brian K. Meyer, New Britain, PA (US);

Robert K. Evans, Bangor, ME (US);

Channing R. Beals, Solana Beach, CA (US);

David C. Kaslow, Seattle, WA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/165 (2006.01); C12N 7/00 (2006.01); A61K 39/25 (2006.01); A61K 39/12 (2006.01); A61K 39/05 (2006.01); A61K 39/08 (2006.01); A61K 39/02 (2006.01); A61K 39/102 (2006.01); A61K 39/13 (2006.01); A61K 39/145 (2006.01); A61K 39/20 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/25 (2013.01); A61K 39/05 (2013.01); A61K 39/08 (2013.01); A61K 39/099 (2013.01); A61K 39/102 (2013.01); A61K 39/12 (2013.01); A61K 39/13 (2013.01); A61K 39/145 (2013.01); A61K 39/165 (2013.01); A61K 39/20 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55 (2013.01); C12N 2710/16734 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/18434 (2013.01); C12N 2770/32634 (2013.01); C12N 2770/36234 (2013.01);
Abstract

The present invention relates to a method of vaccinating a patient against varicella zoster virus (VZV) by delivery of an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of a patient's skin at a depth of between about 100 and about 700 microns from the surface of the skin, which is useful for preventing herpes zoster or reducing the severity or duration thereof. In embodiments of the invention, the patient is 50 years of age or older and has been previously exposed to VZV. The invention also relates to a method of preventing VZV infection in an individual who was not previously infected with VZV comprising administering an effective amount of a live attenuated VZV vaccine to the epidermis or the dermis of the individual's skin at a depth of between about 100 and about 700 microns from the surface of the skin.


Find Patent Forward Citations

Loading…